Skip to main content

Table 1 Patient characteristics of patients who completed all planned procedures. Chi-square and one-way ANOVA was performed for categorical and continuous variables, respectively

From: Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer

 2.0 ± 0.2 MBq/kg with furosemide2.0 ± 0.2 MBq/kg without furosemide4.0 ± 0.4 MBq/kg with furosemide 
Number of patients212120 
Age (median, Q1–Q3)71 (65–74)70.5 (63.5–77.25)69 (63–74)F(2,59) = 0.149, p = 0.862
Weight (mean ± SD)85.1 ± 14.480.9 ± 10.981.5 ± 11.9F(2,59) = 0.691, p = 0.505
StagingΧ2(2, N = 62) = 6.6633, p = 0.03573
 Initial staging0/216/214/20
 Restaging21/2115/2116/20
PSA (ng/mL) (mean ± SD)6.90 ± 9.899.22 ± 18.387.35 ± 10.96F(2,59) = 0.161, p = 0.851
Gleason scoreΧ2(4, N = 62) = 2.8402, p = 0.5849
 ≤ 78/218/219/20
 84/218/215/20
 ≥ 99/215/216/20
Previous treatmentΧ2(8, N = 62) = 6.7322, p = 0.5658
 Prostatectomy   
 Salvage therapy13/2112/2110/20
 Definitive13/219/215/20
 Radiotherapy6/213/217/20
 Current ADT8/213/212/20
 Chemotherapy1/211/210/20